I

Instituto Americas | Rio de Janeiro, Brazil

Research site

(Unclaimed)

Location

Av. Jorge Curi, 550, bloco A, sala 347, Rio de Janeiro, Rio de Janeiro, Brazil

Site insights

Top conditions

Top treatments

Bendamustine

Gemcitabine

Sacituzumab

Prednisone

Taxane

Futibatinib

Doxorubicin

Vincristine

Trastuzumab

Cisplatin

Parent organization

This site is a part of Instituto Americas

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as mon...

Active, not recruiting

Metastatic Colorectal Cancer

Drug: Balstilimab

Drug: Standard of Care

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-1)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Active, not recruiting

Follicular Lymphoma (FL)

Drug: Odronextamab

Drug: Rituximab

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable...

Active, not recruiting

Breast Cancer

Drug: Trastuzumab deruxtecan (T-DXd)

Drug: Ado-trastuzumab emtansine (T-DM1)

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Active, not recruiting

Locally Advanced or Unresectable Metastatic Breast Cancer

Stage IV Breast Cancer

Drug: Paclitaxel

Drug: Capecitabine